A Phase 3 interventional study of meloxicam 0.25 mg/kg and meloxicam 0.125 mg/kg in Arthritis, Juvenile Rheumatoid, sponsored by Boehringer Ingelheim. Completed at 34 sites in 7 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2013-11-01.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Arthritis, Juvenile with a site in Italy — 19 open to participants now, 24 under way, 11 of them phase 3. Arthritis, Juvenile · Italy.
Among the 56 studies in Arthritis, Juvenile with a site in Italy, this one is the 4th largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2000, is one of 28 in phase 3, and was the 3rd registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →19 of the 56 studies in Arthritis, Juvenile with a site in Italy are open now. Recruiting first, the newest first:
Alfasigma S.p.A. · Sites in Italy, Belgium, Czechia and 6 more countries
Ages 8–18
Duke University · Sites in Italy, United States, Germany and 1 more country
Ages 2–21
Novartis Pharmaceuticals · Sites in Italy, United States, Canada and 5 more countries
Ages 1+
Bristol-Myers Squibb · Sites in Italy, United States, Brazil and 8 more countries
Ages 5–17
Meyer Children's Hospital IRCCS · Sites in Italy
Ages 6–18
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 28 · Phase 4 2
First in 2000; this study’s year is marked. 1 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 226 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 90 across the 43 interventional studies, 130 across the 13 observational. Of the 30 that completed or were terminated, 20 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 56 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 2 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Juvenile with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554495Phase 3Alfasigma S.p.A.Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | 2027-06 |
| NCT06618937Istituto Giannina GasliniToward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission | 2027-01-01 |
| NCT07203001Novartis PharmaceuticalsA Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease | 2027-04-22 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies in Arthritis, Juvenile with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A one year double-blind trial to investigate the efficacy and safety of meloxicam oral suspension 0.25 mg/kg and 0.125 mg/kg administered once daily in comparison to naproxen oral suspension 5 mg/kg administered twice daily in children with Juvenile Rheumatoid Arthritis.
Objective: In an international, multicenter, double-blind, randomized clinical trial we evaluated the short-term (3 months) and long term (12 months) efficacy and safety of two doses of meloxicam oral suspension compared with naproxen in children with oligo and polyarticular course juvenile idiopathic arthritis (JIA).
Methods: Children with active oligo or polyarticular course JIA, requiring therapy with an NSAID were eligible for this trial. Patients were randomly allocated to therapy with meloxicam oral suspension 0.125 mg/kg body weight in single daily dose, meloxicam 0.25 mg/kg body weight in single daily dose, or naproxen 10 mg/kg body weight in two daily doses. The trial drugs were administered in a double-blind, double-dummy design for up to 12 months. Response rates were determined according to the American College of Rheumatology Pediatric 30% definition of improvement (ACR Ped 30). Safety parameters were assessed by evaluation of the adverse events in the 3 groups.
Study Hypothesis:
The null hypothesis of interest is that the magnitude of response with regard to the primary endpoint is equivalent between the treatment groups. The alternative is that there is any difference (two-sided) between any of the treatment groups.
Comparison(s):
Naproxen oral suspension 10 mg/kg body weight.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of idiopathic arthritis of childhood by ILAR criteria:
Patients requiring therapy with NSAIDs, i.e., the patient fits into one of the following categories:
Exclusion Criteria:
One of the following therapies during the last 3 months prior to study entry or their intended use during the trial treatment period
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug page: MeloxicamStudies of MeloxicamMeloxicam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Drug page: MeloxicamStudies of MeloxicamMeloxicam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Drug page: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Response rates according to ACR Ped 30
Time frame: after 12 weeks of treatment
Global assessment of overall disease activity by investigator
Time frame: up to 12 months
Parent global assessment of overall well-being
Time frame: up to 12 months
Assessment of functional disability by means of Childhood Health Assessment Questionnaire (CHAQ)
Time frame: up to 12 months
Number of joints with active arthritis
Time frame: up to 12 months
Number of joints with limited range of motion
Time frame: up to 12 months
Erythrocyte Sedimentation Rate (ESR)
Time frame: up to 12 months
Parent global assessment of arthritis
Time frame: up to 12 months
Parent global assessment of pain
Time frame: up to 12 months
Children's assessment of discomfort
Time frame: up to 12 months
Change in functional classification (Steinbrocker classification)
Time frame: up to 12 months
Final global assessment of efficacy by parent
Time frame: week 12, 12 months
Final global assessment of efficacy by investigator
Time frame: week 12, 12 months
Withdrawals due to inadequate efficacy
Time frame: up to 12 months
Paracetamol / acetaminophen consumption
Time frame: up to 12 months
Final global assessment of tolerability by parent
Time frame: week 12, 12 months
Final global assessment of tolerability by investigator
Time frame: week 12, 12 months
Incidence and intensity of adverse events (AEs)
Time frame: 12 months
Incidence of laboratory adverse events
Time frame: 12 months
Withdrawal due to adverse event
Time frame: 12 months
Duration of hospital stay due to gastrointestinal serious adverse event (GI-SAE)
Time frame: week 12, 12 months
Duration of hospital stay due to adverse events related to trial drug administration
Time frame: week 12, 12 months
Additional visits to a physician due to gastrointestinal adverse event (GI-AE)
Time frame: week 12, 12 months
The record gives a start of Sep 2000, a primary completion of Jan 2003 and a completion of Jan 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Meloxicam · Naproxen